Invests in revolutionary
medical device opportunities.

About us

Investing in Medical Innovation

Accuitive Medical Ventures is a venture capital firm with committed capital of $230 million. Our office is located in Atlanta, GA. We're a market driven firm looking for revolutionary medical device technology investment opportunities.

AMV Culture & values

We specialize in two distinct types of investments:

Venture financing for companies with outstanding technology and teams

Venture financing and management of technologies being developed within The Innovation Factory

Accuitive Medical Ventures has a strong relationship with The Innovation Factory (TIF), the successful medical technology serial operating team. TIF has started thirteen companies since 1999 and is based in Atlanta, GA. In conjunction with TIF, Accuitive Medical Ventures has the resources and experience to create long-term value for all medical technology stakeholders.

Accuitive has established relationships with some of the industry’s leading institutions to offer emerging companies and investors the opportunity to build unique new businesses and long-term shareholder value. Accuitive’s connections to some of the industry’s leading practitioners, thought leaders and venture capital firms enable us to add substantial value as investors and board members.

Who we work with:

With the ultimate goal of creating value for our Limited Partners, Accuitive Medical Ventures serves two distinct groups of people:


Passionate, successful teams with strong leadership we can invest in to move exciting technology forward.


creative individuals and groups who would benefit from the business and medical device experience that partnering with The Innovation Factory provides.

What we look for in a partner:

Regardless of whether you’re an entrepreneur looking for an investment in your company or an inventor looking to partner with The Innovation Factory, we look for:

Large Target Market

The device or technology must have the potential to serve a large addressable global market.

Strong Intellectual Property

The technology should be novel with robust intellectual property protection.

Benefitical Technology

The technology should create a new treatment modality or represent a substantial improvement.

Compelling Business Model

The technology should have a business model that provides a sustainable advantage.

Clear Path to Market

The technology must have definable regulatory, clinical, and reimbursement (if applicable) paths.

Multiple Exit Opportunities

The technology must fit an area of strategic need for potential acquirers.

Portfolio of AMV investments

AMV is a business builder. We partner with entrepreneurs and assist them through the growth stages of their businesses towards an exit.

AMV Investments News

Jan 08, 2018 Respicardia Announces First U.S. Commercial Case With The remedē® System

Industry Veteran Peter Sommerness Joins as CEO to Lead U.S. Launch

Dec 18, 2017 Respicardia Closes $58.5 Million In Financing To Treat Central Sleep Apnea

Company announces strategic relationship with ZOLL Medical

Oct 10, 2017 Respicardia's remedē® System Receives FDA Approval

Breakthrough Treatment of Moderate to Severe Central Sleep Apnea in Adult Patients Now Available

May 07, 2018 Sebacia Announces Favorable Ruling by U.S. Court of Appeals for the Federal Circuit Regarding Patent Interference Proceedings with Sienna Biopharmaceuticals, Inc.

The ruling relates to a patent interference proceeding between The General Hospital Corporation (GHC, the owner of certain patents licensed by Sebacia) and Sienna Biopharmaceuticals, Inc.

May 07, 2018 Sebacia Announces $36 Million Equity and Debt Financing to Advance Breakthrough In-Office Procedure for Acne

the company has completed a $20 million Series D financing led by existing investors Versant Ventures, Domain Associates, Accuitive Medical Ventures and Partners Healthcare Innovation Fund

Feb 17, 2017 Ethicon Announces Agreement to Acquire Torax Medical, Inc.

Torax Medical offers an innovative technology for the treatment of Gastroesophageal Reflux Disease (GERD)

The AMV Team

Operating executives with more than 15 years of investment experience from inception to liquidity in the Healthcare Venture/Growth sector
The team’s operating experience guides portfolio investments to:

  1. Identify and Resolve technical challenges
  2. Target markets that are primed for disruption
  3. Drive commercial adoption
  4. Quickly replace ineffectual key employees
  5. Be capital efficient

Team has been together for over a dozen years, and is seasoned, stable, and has a proven track record
Extensive Hands on experience with:

  1. Identifying key market opportunities for novel medical devices
  2. FDA, preparing submissions and responses, panelss
  3. Reimbursement
  4. Clinical trial design and management
  5. Commercializations
  6. Exits

Thomas D. Weldon

Managing Director

Charles E. Larsen

Managing Director

Gordon T. Wyatt

Chief Financial Officer

Cory S. Anderson


Anthony V. Lando


Contact Accuitive Medical Ventures

If your business or technology is ready to partner with AMV, please submit your business plan for review.




295 Premiere Parkway, Suite 100
Atlanta, Ga 30097 USA